Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Bortezomib × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 26 Immunoglobulin Light-chain Amyloidosis 5 Paraproteinemias 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms, Plasma Cell 2 Neoplasms 2 Lymphoproliferative Disorders 2 beta-Thalassemia 1 Waldenstrom Macroglobulinemia 1 Thalassemia 1 Renal Insufficiency 1 Recurrence 1 Multi-centric Castleman's Disease 1 Macular dystrophy, corneal type 1 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell 1 Lymphadenopathy 1 Leukemia, Myeloid, Acute 1 Immunoproliferative Disorders 1 Hematologic Neoplasms 1 HIV Infections 1 Burkitt Lymphoma 1 Anemia, Sickle Cell 1 Amyloidosis 1

Interventions

Cyclophosphamide 10 fludarabine 8 Rituximab 8 Dexamethasone 8 pembrolizumab 7 venetoclax 5 glofitamab 5 Lenalidomide 5 obinutuzumab 4 Etoposide 4 Calcium Dobesilate 4 pomalidomide 3 Temozolomide 3 Doxorubicin 3 Cytarabine 3 zanubrutinib 2 tocilizumab 2 tisagenlecleucel 2 selinexor 2 ruxolitinib 2 ibrutinib 2 enzalutamide 2 dexamethasone acetate 2 dexamethasone 21-phosphate 2 carfilzomib 2 abemaciclib 2 Vincristine 2 Surgical Procedures, Operative 2 Radiotherapy 2 Prednisone 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05519085 2026-03-11

SUCCESSOR-1

Celgene

Phase 3 Recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡